Following final registration of acceptances, the final acceptance level in Karo Pharma AB's ("Karo Pharma") voluntary offer ("Voluntary Offer") to acquire all shares in Weifa ASA ("Weifa") is 35,463,139 shares representing 97.23% of the total shares in Weifa on a fully diluted basis.
It is expected that the settlement of the Voluntary Offer will take place on or about 6 October 2017 and that the cash consideration will be available on the accepting Weifa shareholders' registered bank accounts in the VPS on or about 9 October 2017.
Upon settlement of the Voluntary Offer, Karo Pharma will hold more than 90% of all the shares in Weifa. Karo Pharma intends to initiate a compulsory acquisition of the remaining outstanding shares of Weifa at a price equal to the offer price of NOK 35 per share, and to propose that Weifa applies for a delisting of its shares from Oslo Børs.
For further information, please contact:
Peter Blom, CEO of Karo Pharma, +46 070-655 56 98 or email@example.com
Simen Nyberg-Hansen, CFO of Weifa: +47 9820 6355, or firstname.lastname@example.org